<?xml version="1.0" encoding="UTF-8"?>
<p>The patient has been placed for two months under a four-drug anti-tuberculosis regimen made from Isoniazid (H/Inh), Rifampin (R/Rif), Pyrazinamide (Z/Pza), and Ethambutol (E/Etb), followed by a dual therapy based on Isoniazid and Rifampin. After two months, the clinical outcome was favourable with an improvement of the general condition, a decrease in the extent of skin lesions' and a partial regression of lymphedema starting from the fourth month of treatment.</p>
